Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Mallinckrodt Dropped 12% Today

By Brian Orelli, PhD – Aug 15, 2019 at 4:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Positive clinical-trial results couldn't save the embroiled biotech.

What happened

Shares of Mallinckrodt (MNK) closed down 12% on Thursday despite the company reporting positive results from the phase 3 Confirm clinical trial of its drug candidate terlipressin in patients with hepatorenal syndrome type 1 (HRS-1), a disease that stems from liver issues and often results in kidney failure and death.

So what

Mallinckrodt was light on the details from the Confirm study -- it's saving them for a medical meeting -- but the company said the clinical trial met its primary endpoint of verified HRS-1 reversal, which requires improvement in kidney function, avoidance of dialysis, and short-term survival.

Today's decline may be because investors are worried about Mallinckrodt holding back the data, but given the lack of drugs approved to treat HRS-1 and the severity of the disease -- median survival is less than two weeks and 80% of patients die within the first three months -- any improvement over placebo is likely to lead regulators to approve the drug.

On the other hand, the details of the trial will ultimately be important for how much revenue Mallinckrodt can generate from terlipressin, since the efficacy will affect how much Mallinckrodt can charge for the drug. Improving survival by a few days isn't worth nearly as much as a long-term cure.

Doctor showing a report to a patient in a hospital bed

Image source: Getty Images.

Now what

While today's move comes following the release of top-line results from the Confirm study, today's double-digit decline may have nothing to do with the news, given the company's extreme volatility. Mallinckrodt is embroiled in opioid lawsuits and is in a fight with the Centers for Medicare and Medicaid Services over coverage of its Acthar Gel by Medicaid. Investors may be taking the lack of a post-news share-price pop as a sign they should move on.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mallinckrodt Public Limited Company Stock Quote
Mallinckrodt Public Limited Company

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.